Ireland-based biopharmaceutical company Jazz Pharmaceuticals has appointed Russell Cox to the newly created position of Chief Operating Officer (COO). Cox, who joined the company in July 2010, was most recently EVP and Chief Commercial Officer. He will continue to report to Bruce Cozadd, Chairman and Chief Executive, and will take global responsibility for the company's commercial, research and development (R&D) and technical operations.
Prior to joining Jazz, Cox was SVP and Chief Commercial Officer at Ipsen Group following its acquisition of Tercica. He was also VP of Marketing at Scios, which was acquired by Johnson and Johnson, and held several escalating leadership roles at Genentech, including new product development and product team leader. In 2013, he joined the Board of Vascular Cures, a non-profit organisation focused on investing in breakthrough treatments for vascular disease.
Cox has broad leadership experience in multiple areas, including central nervous system disease, haematology/oncology, endocrinology, and cardiovascular disease.
'This is the right time to introduce a chief operating officer position, as it will be instrumental to managing our expanding global operations and the diversification of our R&D and commercial franchises, including the recent additions of Defitelio in the European Union and JZP-110,' said Cozadd.
